Epizyme, Inc.
EPZMDelisted- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001571498
Epizyme, Inc. was delisted in 2022; its insiders filed their last Form 4 on Aug 16, 2022; 94 institutions reported holding it in 13F filings for Q2 2022, worth $187.0M in total; no superinvestor held it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Epizyme, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 0 filings
- Insiders trading
- 0
- Net value
- $0
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Epizyme, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| RP Management, LLC | Director, 10% Owner | 0Indirect | Aug 16, 2022 | 0 |
| Legorreta Pablo G. | Director, 10% Owner | 0Indirect | Aug 16, 2022 | 0 |
| RPI Finance Trust | Director, 10% Owner | 0Indirect | Aug 16, 2022 | 0 |
| Royalty Pharma Investments 2019 ICAV | Director, 10% Owner | 0Indirect | Aug 16, 2022 | 0 |
| Goldfischer Carl | Director | 0Indirect | Aug 16, 2022 | 0 |
| Bate Kenneth | Director | 0 | Aug 16, 2022 | 0 |
| Mott David M | Director | 0Indirect | Aug 16, 2022 | 0 |
| Conroy Kevin T | Director | 0 | Aug 16, 2022 | 0 |
| Beveridge, Roy A | Director | 0 | Aug 16, 2022 | 0 |
| Bogle Grant C. | President and CEO | 0 | Aug 16, 2022 | 0 |
| Kutok Jeffery | Chief Scientific Officer | 0 | Aug 16, 2022 | 0 |
| Giordano Michael F | Director | 0 | Aug 16, 2022 | 0 |
| Agarwal Shefali | Other: See Remarks | 0 | Aug 16, 2022 | 0 |
| Beaulieu Joseph | See Remarks | 0 | Aug 16, 2022 | 0 |
| Korn Jerald | Chief Operating Officer | – | Aug 16, 2022 | 0 |
| Richon Victoria | Director | 0 | Aug 16, 2022 | 0 |
| Stuckley Carol | Director | 0 | Aug 16, 2022 | 0 |
| Ros Matthew | See Remarks | 111,313 | Aug 18, 2021 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Apr 13, 2022 (view filing) | Apr 11 | 2 days | Kutok JefferyChief Scientific Officer | SSaleCommon Stock, par value $0.0001 | −2.74K | $0.90 | −$2.47K | −2.8%94.6K after | |
| Feb 9, 2022 (view filing) | Feb 7 | 2 days | Beaulieu JosephCorporate Controller | SSaleCommon Stock, par value $0.0001 | −222 | $1.50 | −$333 | −0.8%28.6K after | |
| Feb 9, 2022 (view filing) | Feb 7 | 2 days | Agarwal ShefaliSee Remarks | SSaleCommon Stock, par value $0.0001 | −1.06K | $1.50 | −$1.59K | −0.7%156.4K after | |
| Feb 4, 2022 (view filing) | Feb 2 | 2 days | Agarwal ShefaliSee Remarks | SSaleCommon Stock, par value $0.0001 | −2.64K | $1.37 | −$3.62K | −1.6%157.4K after | |
| Feb 4, 2022 (view filing) | Feb 2 | 2 days | Kutok JefferyChief Scientific Officer | SSaleCommon Stock, par value $0.0001 | −2.56K | $1.37 | −$3.50K | −2.6%97.3K after | |
| Feb 4, 2022 (view filing) | Feb 2 | 2 days | Beaulieu JosephCorporate Controller | SSaleCommon Stock, par value $0.0001 | −687 | $1.37 | −$941.19 | −2.3%28.9K after | |
| Feb 1, 2022 (view filing)4:17 PM ET | Jan 31 | 1 day | Legorreta Pablo G. and 2 othersDirector, 10% Owner | PPurchase | +22.7M | $1.50 | +$34.0M | +247.3%31.8M after | |
| Jan 28, 2022 (view filing) | Jan 26 | 2 days | Agarwal ShefaliSee Remarks | SSaleCommon Stock, par value $0.0001 | −2.92K | $2.02 | −$5.90K | −1.8%160.1K after | |
| Dec 7, 2021 (view filing) | Dec 6 | 1 day | Agarwal ShefaliSee Remarks | SSaleCommon Stock, par value $0.0001 | −1.78K | $2.93 | −$5.22K | −1.1%163.0K after |